PRALUENT – alirocumab 75 mg/mL and 150 mg/mL soln for inj - sanofi-aventis

• Praluent offers 2 starting doses to choose the power you need with 2 levels of LDL-C lowering
• Praluent helps to achieve rapid and sustained LDL-C reductions with:
- Praluent 75 mg offers powerful LDL-C reduction of >50%¹
- Praluent 150 mg when >60% LDL-C reduction needed¹

References:
1. In adults with primary hypercholesterolaemia (heterozygous familial and nonfamilial) or mixed dyslipidaemia, as an adjunct to diet: in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
2. References on file.

Further information is available in section 2l, New In This Issue and mims.com.
Full prescribing information is available upon request.